National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Glecaprevir/pibrentasvir (Maviret®) is licensed for the treatment of chronic hepatitis C virus (HCV) infection in adults – pangenotypic GT1-6.

NCPE Assessment Process Complete
Rapid review received 11/07/2017
Rapid review completed 17/08/2017
Rapid Review outcome Full pharmacoeconomic assessment not recommended